137 related articles for article (PubMed ID: 7783880)
1. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
[TBL] [Abstract][Full Text] [Related]
3. GM1 ganglioside in the treatment of Parkinson's disease.
Schneider JS
Ann N Y Acad Sci; 1998 Jun; 845():363-73. PubMed ID: 9668369
[TBL] [Abstract][Full Text] [Related]
4. GM1 ganglioside in Parkinson's disease: Results of a five year open study.
Schneider JS; Sendek S; Daskalakis C; Cambi F
J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.
Schneider JS; Gollomp SM; Sendek S; Colcher A; Cambi F; Du W
J Neurol Sci; 2013 Jan; 324(1-2):140-8. PubMed ID: 23199590
[TBL] [Abstract][Full Text] [Related]
6. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.
Schneider JS; Cambi F; Gollomp SM; Kuwabara H; Brašić JR; Leiby B; Sendek S; Wong DF
J Neurol Sci; 2015 Sep; 356(1-2):118-23. PubMed ID: 26099170
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside GM1 in acute ischemic stroke. The SASS Trial.
Stroke; 1994 Jun; 25(6):1141-8. PubMed ID: 8202971
[TBL] [Abstract][Full Text] [Related]
8. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.
Schneider JS
Glycoconj J; 2022 Feb; 39(1):13-26. PubMed ID: 34037912
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic hyperlipidaemia with GM1 ganglioside.
Roberts JW; Hoeg JM; Mouradian MM; Linfante I; Chase TN
Lancet; 1993 Jul; 342(8863):115. PubMed ID: 8100881
[No Abstract] [Full Text] [Related]
10. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Schneider JS; Seyfried TN; Choi HS; Kidd SK
PLoS One; 2015; 10(12):e0143351. PubMed ID: 26629687
[TBL] [Abstract][Full Text] [Related]
11. Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
Wu G; Lu ZH; Seo JH; Alselehdar SK; DeFrees S; Ledeen RW
Exp Neurol; 2020 Jul; 329():113284. PubMed ID: 32165255
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.
Ba XH
Int J Neurosci; 2016; 126(2):163-7. PubMed ID: 25495991
[TBL] [Abstract][Full Text] [Related]
13. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Schneider JS
J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
[TBL] [Abstract][Full Text] [Related]
14. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
15. The Key Role of GM1 Ganglioside in Parkinson's Disease.
Chowdhury S; Ledeen R
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204675
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Wu G; Lu ZH; Kulkarni N; Ledeen RW
J Neurosci Res; 2012 Oct; 90(10):1997-2008. PubMed ID: 22714832
[TBL] [Abstract][Full Text] [Related]
17. GM1 ganglioside for acute ischemic stroke. Trial design issues.
Alter M
Ann N Y Acad Sci; 1998 Jun; 845():391-401. PubMed ID: 9668372
[TBL] [Abstract][Full Text] [Related]
18. Is ganglioside GM1 effective in the treatment of stroke?
Braune S
Drugs Aging; 1991 Jan; 1(1):57-66. PubMed ID: 1794005
[TBL] [Abstract][Full Text] [Related]
19. Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson's Disease?
Alselehdar SK; Chakraborty M; Chowdhury S; Alcalay RN; Surface M; Ledeen R
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768952
[TBL] [Abstract][Full Text] [Related]
20. GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms.
Schneider JS
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
